Janssen Biotech Inc.

10/16/2023 | Press release | Distributed by Public on 10/16/2023 06:59

TREMFYA® (guselkumab) Maintains Key Efficacy Endpoints Through Three Years for Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study